OTC Medicines

Select an Issue

Browse OTC Medicines Content

Smiling group of women

Press Releases and Statements

CHPA Applauds Historic FDA Approval of First-Ever OTC Daily Oral Contraceptive

Consumer Healthcare Products Association (CHPA) President and CEO Scott Melville today released the below statement following the U.S. Food and Drug Administration (FDA) approving Opill®

Jul 13, 2023

FDA headquarters sign in Washington DC

Submission

Comments Regarding Identification, Assessment, and Control of Nitrosamine Drug Substance-Related Impurities in Human Drug Products

CHPA thanks FDA for providing a process to give feedback from industry leveraging science and risk-based approaches to appropriately identify, assess and control (where needed) NDSRIs and preventing unacceptable levels of nitrosamines in drug products.

Jul 3, 2023

A picture of generic OTC medicines

Submission

Comments Regarding OTC Monograph Order Request (OMORs): Format and Content

Industry appreciates this guidance to enable the assembly of suitable and successful OMORs. FDA must adopt standards and expectations consistent with the intent of OMUFA, rather than the NDA paradigm, with which it is very familiar.

Jun 12, 2023

CHPA Impacts Spring 2023 teaser image

Infographic

CHPA Impacts Spring 2023

May 17, 2023

red capsules being sorted in a circular hopper

Submission

Comments Regarding CSPI Synthetic Dye Petition

CHPA appreciates this opportunity to comment on the Synthetic Dye Petition submitted to the California Department of Public Health requesting that a warning be placed on food and dietary supplement products related to adverse neurobehavioral effects purportedly associated with ingestion of synthetic food dyes.

May 12, 2023

Group of Four Professionals in a Corporate Setting sitting in blue chairs

Submission

OTC Meetings and Events of NDAC and Other Advisory Committees: Index by Ingredient

May 10, 2023

Millennial black businesswoman addressing colleagues at a corporate business meeting

Submission

Chronology: OTC Meetings and Events to NDAC and Other Advisory Committees

May 10, 2023

FDA headquarters sign in Washington DC

Press Releases and Statements

CHPA Applauds FDA Advisory Panel’s Unanimous Recommendation to Approve First-Ever OTC Daily Oral Contraceptive

CHPA today released the below statement following a U.S. Food and Drug Administration (FDA) joint advisory committee meeting, which concluded that Opill®, a once-daily oral contraceptive, should be approved as the first oral contraceptive for use without a prescription:  

May 10, 2023

chpa chat logo on blue background

Podcast

CHPA Chat - Preserving Your Smile: The Importance of Gum Health

Ellen Guritzky and Anousheh Alavi from Haleon, with CHPA's Anita Brikman, discuss the importance of preserving gum health to avoid tooth loss. Catch the full conversation on this episode of CHPA Chat.

May 8, 2023

FDA headquarters sign in Washington DC

Press Releases and Statements

CHPA Statement on FDA Releasing Briefing Materials for OPILL Joint Advisory Committee Meeting

The Consumer Healthcare Products Association (CHPA) today released the below statement following the U.S. Food and Drug Administration’s (FDA) public release of briefing materials

May 5, 2023

Filter Results